Printer Friendly

NOVO NORDISK AND MINIMED ESTABLISH COOPERATION ON INSULIN INFUSION THERAPY

 BAGSVAERD, Denmark and SYLMAR, Calif., Jan. 22 /PRNewswire/ -- Novo Nordisk A/S (NYSE: NVO) and MiniMed Inc. announced today a worldwide cooperation agreement to jointly market diabetes products for insulin infusion therapy (facilitated by an integrated system of insulin, external insulin pump, and accessories) and to work together toward developing and marketing new products to further improve this therapy. The cooperation is effective immediately in Europe and will be phased-in over an appropriate period of time in other regions of the world.
 Novo Nordisk is the world's leading manufacturer of insulin and insulin injection systems and MiniMed is the world's leading manufacturer of external and implantable insulin pumps and accessories. This agreement allows both companies to fulfill the specialized needs of individuals with diabetes by developing and marketing unique and innovative products for insulin infusion therapy. As a result of the agreement, it is estimated that the combined strength of both companies will effectively benefit more than two-thirds of the world's diabetics for whom insulin infusion therapy is prescribed.
 Under the terms of the agreement, Novo Nordisk and MiniMed will work together on a country-by-country basis in marketing, distributing and servicing the current and future range of MiniMed pumps and accessories and Novo Nordisk pump insulin. While Novo Nordisk currently markets its own insulin pump and accessories, it is the intention that these sales will be phased out. However, Novo Nordisk will continue to supply its pump insulin and corresponding services for use with MiniMed products. A European service center for MiniMed products will also be established in Denmark in the future. MiniMed products in the rest of the world will continue to be serviced by MiniMed in California.
 Today, it is estimated that more than 25,000 people with diabetes worldwide are prescribed insulin infusion therapy. One of the basic advantages of this therapy is a continuous basal and bolus delivery of insulin into the body which mimics the natural pattern of insulin release found in non-diabetics, thereby facilitating improved blood glucose control. Insulin infusion therapy also frees people with diabetes from the restrictions of rigid schedules for eating, sleeping, and exercise.
 Novo Nordisk A/S is a major force in insulin production and diabetes care and is the world's largest producer of industrial enzymes. The company also manufactures and markets a variety of other pharmaceutical and bioindustrial products. Headquartered in Denmark, Novo Nordisk employs more than 10,000 people in over 40 countries and markets its products in 130 countries. Its B shares are listed on the stock exchanges in Copenhagen, London, Basel, Zurich and Geneva. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO."
 MiniMed Technologies is the world leader in the design and manufacture of external and implantable insulin pumps for the treatment of patients with diabetes. Today, more than 15,000 insulin pump users enjoy the therapeutic advantages and lifestyle flexibility afforded by improved control of blood glucose with the MiniMed external insulin pump. In addition to the insulin pump, MiniMed has developed a complete line of pump accessory products which includes the Sof-set(TM) needle- free infusion set and Polyfin(TM) insulin compatible tubing. The MiniMed implantable insulin pump is currently undergoing clinical investigation and testing in the United States and has been implanted in over 400 patients worldwide.
 -0- 1/22/93
 /CONTACT: Margaret Jo Ringsted of Novo Nordisk of North America, 212-867-0123, or fax 212-986-6499, or Peter Verrengia of Fleishman- Hillard, 212-265-9150, or fax 212-245-0704, for Novo Nordisk of North America/
 (NVO)


CO: Novo Nordisk A/S; MiniMed Inc. ST: California IN: MTC SU: JVN

TS-TM -- NY004 -- 7807 01/22/93 10:03 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 22, 1993
Words:607
Previous Article:TENNANT NAMED ONE OF 100 BEST
Next Article:NEW BOOK LISTS AVIS AS ONE OF 'THE 100 BEST COMPANIES TO WORK FOR IN AMERICA'
Topics:


Related Articles
ANERGEN AND NOVO NORDISK ENTER INTO MULTIPRODUCT COLLABORATION
NOVO NORDISK RECEIVES APPROVAL TO MARKET INSULIN PRODUCT FOR USE IN EXTERNAL INSULIN INFUSION PUMPS
TWO LEADERS IN DIABETES CARE ANNOUNCE WORLDWIDE DISEASE MANAGEMENT AGREEMENT
Schering-Plough and Novo Nordisk Announce Copromotion Agreement For PRANDIN(TM) and Diabetes Care Products
Prandin(TM), New Oral Treatment for Type 2 Diabetes, Now Available in the US
Novo Nordisk Submits New Drug Application for Recombinant Velosulin(R)BR
Novo Nordisk Presents New Insulin Delivery System.
NOVORAPID APPROVED FOR PUMP THERAPY IN THE EU.
First and Only Insulin Analog Approved for Pump Therapy; New Indication for NovoLog(R) (insulin aspart [rDNA origin] injection) Offers Additional...
Study Shows Rapid-Acting Insulin Analog Insulin Aspart Equally Effective And Safe in Pump Therapy or Multiple Daily Injections For Treatment of Type...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters